NARA Discovery
Article Details
← Back to Search Results
Journal Article

Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel

Saeed Manoochehri; Behrad Darvishi; Golnaz Kamalinia; Mohsen Amini; Mahdieh Fallah; Seyed Naser Ostad; Fatemeh Atyabi; Rassoul Dinarvand
DARU Journal of Pharmaceutical Sciences · Vol. 21, Issue 1 · 2013

Abstract

Background Poly lactic-co-glycolic acid (PLGA) based nanoparticles are considered to be a promising drug carrier in tumor targeting but suffer from the high level of opsonization by reticuloendothelial system due to their hydrophobic structure. As a result surface modification of these nanoparticles has been widely studied as an essential step in their development. Among various surface modifications, human serum albumin (HSA) possesses advantages including small size, hydrophilic surface and accumulation in leaky vasculature of tumors through passive targeting and a probable active transport into tumor tissues. Methods PLGA nanoparticles of docetaxel were prepared by emulsification evaporation method and were surface conjugated with human serum albumin. Fourier transform infrared spectrum was used to confirm the conjugation reaction where nuclear magnetic resonance was utilized for conjugation ratio determination. In addition, transmission electron microscopy showed two different contrast media in conjugated nanoparticles. Furthermore, cytotoxicity of free docetaxel, unconjugated and conjugated PLGA nanoparticles was studied in HepG2 cells. Results Size, zeta potential and drug loading of PLGA nanoparticles were about 199 nm, −11.07 mV, and 4%, respectively where size, zeta potential and drug loading of conjugated nanoparticles were found to be 204 nm, −5.6 mV and 3.6% respectively. Conjugated nanoparticles represented a three-phasic release pattern with a 20% burst effect for docetaxel on the first day. Cytotoxicity experiment showed that the IC50 of HSA conjugated PLGA nanoparticles (5.4 μg) was significantly lower than both free docetaxel (20.2 μg) and unconjugated PLGA nanoparticles (6.2 μg). Conclusion In conclusion surface modification of PLGA nanoparticles through HSA conjugation results in more cytotoxicity against tumor cell lines compared with free docetaxel and unconjugated PLGA nanoparticles. Albumin conjugated PLGA nanoparticles may represent a promising drug delivery system in cancer therapy.

Bibliographic Information

JournalDARU Journal of Pharmaceutical Sciences
PublisherSpringer
Publication Date2013-12-01
Publication Year2013
Volume21
Issue1
Document TypeJournal Article
eISSN2008-2231
DOI10.1186/2008-2231-21-58

Access Information

NARA Access Coverage2012-01-01~Current
Journal Homepagehttps://www.springer.com/journal/40199
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.